CorMedix (CRMD) executive compensation, 2026 proxy

Joseph Todisco, Chief Executive Officer, was paid $6.1M in 2025, up 159% from $2.4M the year before.

Filed
April 29, 2026
Pay year
2025
Named executives
3
CEO total pay
$6.1M+159% vs prior year
CEO pay in equity
74%$4.5M in awards
2025 Revenue
$311.7MIncludes DefenCath and Melinta portfolio
2025 Net Income
$163.0MCompared to prior net loss
CEO Stock Awards
$4,492,500Grant date fair value
CEO Non-Equity Incentive
$865,072Earned for fiscal year

How Todisco was paid

$6.1M in total for 2025, as reported in the Summary Compensation Table. Equity awards are valued at grant, not at what they turned out to be worth.

Salary11%Stock awards74%Non-equity incentive14%All other compensation1%

Named executive officers

ExecutiveTotal
Joseph TodiscoChief Executive Officer$6,101,176
Elizabeth HurlburtExecutive Vice President, Chief Operating Officer$3,743,688
Beth Zelnick KaufmanExecutive Vice President, Chief Legal/Compliance Officer & Corp. Secretary$3,765,910

What changed and why

  • $6.1MJoseph Todisco received total compensation of $6,101,176 in fiscal year 2025.
  • $311.7MTotal revenue reached $311.7 million following successful commercialization and the Melinta acquisition.
  • $163.0MNet income was $163.0 million compared to a net loss previously.
  • Named Executive Officers were granted both restricted stock units and performance stock units.

About this page

Figures are automated and can be wrong; check the filing for the exact numbers. Totals follow SEC rules, which value stock and option awards at grant. Read the DEF 14A proxy statement for footnotes and the compensation committee's full reasoning.